Results 211 to 220 of about 3,843,324 (325)

Nonlinear Stability in a Free Boundary Model of Active Locomotion. [PDF]

open access: yesArch Ration Mech Anal
Berlyand L, Safsten CA, Truskinovsky L.
europepmc   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

open access: yesMolecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He   +8 more
wiley   +1 more source

Exploring and explaining nurses' resilience and developing strategies for its enhancement: an explanatory sequential mixed method study. [PDF]

open access: yesBMC Nurs
Khaleghparast S   +7 more
europepmc   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

Positive and maximal positive solutions of singular mixed boundary value problem

open access: yesOpen Mathematics, 2009
Agarwal Ravi   +2 more
doaj   +1 more source

Positive solutions for parametric singular Dirichlet(p,q)-equations

open access: green, 2020
Νικόλαος Παπαγεωργίου   +2 more
openalex   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy